Luminex Co. (LMNX) Director Sells $216,466.83 in Stock

Luminex Co. (NASDAQ:LMNX) Director G Walter Loewenbaum II sold 10,503 shares of the business’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $20.61, for a total value of $216,466.83. Following the completion of the sale, the director now owns 564,217 shares in the company, valued at $11,628,512.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

G Walter Loewenbaum II also recently made the following trade(s):

  • On Thursday, December 14th, G Walter Loewenbaum II sold 31,739 shares of Luminex stock. The shares were sold at an average price of $20.49, for a total value of $650,332.11.
  • On Tuesday, December 12th, G Walter Loewenbaum II sold 39,456 shares of Luminex stock. The shares were sold at an average price of $20.40, for a total value of $804,902.40.
  • On Thursday, November 16th, G Walter Loewenbaum II sold 50,000 shares of Luminex stock. The shares were sold at an average price of $21.79, for a total value of $1,089,500.00.

Shares of Luminex Co. (NASDAQ LMNX) traded down $0.06 during midday trading on Thursday, hitting $20.53. The stock had a trading volume of 144,000 shares, compared to its average volume of 201,956. The stock has a market capitalization of $907.08, a PE ratio of 35.50, a PEG ratio of 2.59 and a beta of 0.19. Luminex Co. has a one year low of $17.68 and a one year high of $22.42.

Luminex (NASDAQ:LMNX) last announced its quarterly earnings results on Monday, October 30th. The medical instruments supplier reported $0.25 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.19 by $0.06. The company had revenue of $74.14 million during the quarter, compared to analysts’ expectations of $74.38 million. Luminex had a return on equity of 6.01% and a net margin of 9.52%. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.21 earnings per share. equities analysts anticipate that Luminex Co. will post 0.49 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 12th. Stockholders of record on Friday, December 22nd will be given a $0.06 dividend. This represents a $0.24 annualized dividend and a dividend yield of 1.17%. The ex-dividend date of this dividend is Thursday, December 21st. Luminex’s dividend payout ratio (DPR) is presently 36.36%.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Algert Global LLC grew its position in shares of Luminex by 18.2% in the third quarter. Algert Global LLC now owns 129,997 shares of the medical instruments supplier’s stock valued at $2,643,000 after purchasing an additional 20,043 shares in the last quarter. Neuberger Berman Group LLC grew its position in Luminex by 9.6% during the third quarter. Neuberger Berman Group LLC now owns 1,015,916 shares of the medical instruments supplier’s stock worth $20,654,000 after buying an additional 89,141 shares in the last quarter. OxFORD Asset Management LLP grew its position in Luminex by 4.3% during the third quarter. OxFORD Asset Management LLP now owns 194,526 shares of the medical instruments supplier’s stock worth $3,937,000 after buying an additional 7,964 shares in the last quarter. Elk Creek Partners LLC grew its position in Luminex by 13.6% during the third quarter. Elk Creek Partners LLC now owns 871,429 shares of the medical instruments supplier’s stock worth $17,716,000 after buying an additional 104,494 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Luminex by 3.5% during the third quarter. Dimensional Fund Advisors LP now owns 1,819,417 shares of the medical instruments supplier’s stock worth $36,989,000 after buying an additional 61,437 shares in the last quarter. Institutional investors own 79.16% of the company’s stock.

Several brokerages have issued reports on LMNX. TheStreet upgraded Luminex from a “c+” rating to a “b-” rating in a research note on Wednesday, November 1st. BidaskClub lowered Luminex from a “hold” rating to a “sell” rating in a research note on Wednesday, December 6th. Jefferies Group reiterated a “hold” rating and issued a $21.00 price target on shares of Luminex in a research report on Friday, October 20th. ValuEngine upgraded Luminex from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th. Finally, Zacks Investment Research upgraded Luminex from a “hold” rating to a “strong-buy” rating and set a $22.00 price target for the company in a research report on Thursday, August 24th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $20.00.

COPYRIGHT VIOLATION WARNING: This report was first reported by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.com-unik.info/2017/12/21/luminex-co-lmnx-director-sells-216466-83-in-stock.html.

Luminex Company Profile

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Insider Buying and Selling by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit